Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

A highly collaborative investment professional and research analyst with 10+ years of international experience in equity research, treasury operations, and trading positions across multiple asset classes at leading multinational banks Citibank and Morgan Stanley, UHNWI-backed family office and European independent equity research firm. A respectable background in equity capital markets, corporate treasury, investment banking operations, equity research analysis and portfolio management.

Genscript Biotech Placement - Raising Money to Build Up CAR-T R&D and Production Facilities

Genscript Biotech IPO - Financial Track Record Doesn't Inspire Much Confidence

Algosun Global

Equity Bottom-Up

<p>Biotech company <a href="https://www.smartkarma.com/entities/legend-biotech-corp" target="_blank" data-smartkarma-citation="entities:28963:1" rel="noopener">Legend Biotech Corp (LEGN US)</a> , a subsidiary of <a href="https://www.smartkarma.com/entities/genscript-biotech-corp" target="_blank" data-smartkarma-citation="entities:21041:1" rel="noopener">Genscript Biotech (1548 HK)</a> , started Phase 1 clinical trial in the United States for its product candidate LB1901 for the treatment of relapsed T-Cell Lymphoma, the subtype of non-Hodgkin’s lymphoma. In our insight we will focus on the business of Genscript Biotech and forecast sales of LB1901 in the United States, Europe and Greater China. </p>

Biotech company Legend Biotech Corp (LEGN US) , a subsidiary of Genscript Biotech (1548 HK) , started Phase 1 clinical trial in the United States for its product candidate LB1901 for the treatment of relapsed T-Cell Lymphoma, the subtype of non-Hodgkin’s lymphoma. In our insight we will focus on the business of Genscript Biotech and forecast sales of LB1901 in the United States, Europe and Greater China. 

Global #1 Gene Synthesis Provider, But The Stock Is Fairly Valued